
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PCS12852
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Recipient : Processa Pharmaceuticals
Deal Size : $455.0 million
Deal Type : Licensing Agreement
Processa Pharmaceuticals Signs Binding Term Sheet agreement with Intact Therapeutics
Details : The agreement grants Intact the exclusive option to license PCS12852, a best-in-class 5-HT4 receptor agonist for gastroparesis and other gastrointestinal motility disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 17, 2025
Lead Product(s) : PCS12852
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Recipient : Processa Pharmaceuticals
Deal Size : $455.0 million
Deal Type : Licensing Agreement

Contact Us!